ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Japan nears homegrown vaccine with Daiichi Sankyo Phase 3 trials

Shionogi eyes enough COVID shots for 60m people a year

TOKYO -- Daiichi Sankyo plans to begin Phase 3 clinical trials for its coronavirus vaccine this autumn with the aim of bringing it to the public in 2022, finally pushing forward Japan's effort to locally develop COVID-19 shots.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more